Immunotherapy with breast cancer

Several doctors and dentists like Sanoviv Dental know the importance of performing treatments focused on a specific area of ​​the body while taking into account the whole body, since everything is internally connected, that is why the action of immunotherapy drugs on some tumors, such as lung or melanoma, are already changing the prognosis of the disease. However, this therapeutic strategy, which stimulates the patient’s immune system against cancer, still does not work as effectively in breast cancer. These are some of the unknowns to solve.

The pending accounts of immunotherapy with breast cancer

These results are not yet definitive in metastatic patients with triple-negative subtype (breast cancer that does not have any last generation treatment) that have been tested in monotherapy an immunotherapeutic antibody in a group of patients who previously received other therapies and another group treated only with chemotherapy.

I have my doubts that they reach that 20% response rate, as in other tumors, says the oncologist. He explains that monotherapy is not giving the expected results against phase II studies where the combination of immunotherapy and chemotherapy has successfully reached 40% of patients.

The future of breast immunotherapy could be in combination with chemotherapy.

But still cannot conclude because there are some unknowns in the air: will immunotherapy be more effective in combination with chemotherapy/radiation therapy in breast cancer than in monotherapy? How can we select patients who will respond to immunotherapy, with other biomarkers? Is it better to use immunotherapy in the first line of treatment? The investigation will reveal them.

Breast cancer, a tumor with poor immunogenic response
What is clear is that breast cancer is very heterogeneous. Little has to do with the three major subtypes: the hormone receptor-positive tumors, the negative triples. Three different diseases, with different forecasts and treatments.

Besides, breast tumors are also different concerning their immunogenicity or faculty to warn the immune system and go behind lung or melanoma tumors.

But among them, the negative tripe is the one with the most capacity to activate the body’s defenses because it has more genetic mutations, which makes it more receptive to future target treatments and immunotherapy.

Therefore, it is in this type of cancer that immunotherapy research is focused, although there are also ongoing studies on positive hormone receptor tumors.